MIND PUBLICATIONS
Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-Label Clinical Trial
November 04, 2020
We are excited to share that a set of findings from the open label phase of our clinical trial assessing a full-spectrum, high-CBD/low-THC product were recently published in JAMA Psychiatry! These findings show that 50% of individuals enrolled in the clinical trial tested positive for THC on a urinary drug assay after using the the sublingual solution for four weeks. Positive THC findings occurred in some individuals although the study product contains far less THC than is allowable for hemp-based products in the US. More research is needed to understand which variables may contribute to positive findings in some individuals, but not others.
The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment
January 22, 2018
We are pleased to announce that Frontiers has just published our second paper from the MIND program. This marks the first neuroimaging study in MMJ patients, documenting potential normalization of brain activity during the Multi-Source Interference Task (MSIT), a measure of executive function, after three months of MMJ treatment.
Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function
October 13, 2016
The first publication from the MIND program was published today in Frontiers in Pharmacology! After 3 months of medical marijuana treatment, MMJ patients demonstrated improvements in clinical state, cognition, quality of life and other health-related measures. Decreased use of conventional pharmaceutical medications was also noted among study patients.